NA
VRTX icon

Nautilus Advisors’s Vertex Pharmaceuticals VRTX Stock Holding History

Nautilus Advisors’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$377K Hold
777
– – 0.22% 117
2026
Q1 		$347K Buy
777
+67
+9% +$31.2K 0.24% 108
2025
Q4 		$322K Buy
710
+50
+8% +$21.6K 0.21% 124
2025
Q3 		$258K Sell
660
-41
-6% -$17.1K 0.17% 144
2025
Q2 		$312K Buy
701
+235
+50% +$108K 0.23% 122
2025
Q1 		$226K Buy
+466
New +$217K 0.19% 140

Other funds holding VRTX

Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
Handelsbanken Fonder
Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return
DC
Davenport & Co Richmond, Virginia $20.4B AUM 18.11% 1-Year Est. Return
CTB
Country Trust Bank Bloomington, Illinois $5.71B AUM 25.48% 1-Year Est. Return
CNB
Czech National Bank Prague, Czech Republic $18.3B AUM 43.04% 1-Year Est. Return
GIA
Gateway Investment Advisers Cincinnati, Ohio $10.1B AUM 40.26% 1-Year Est. Return
MLL
Moody Lynn & Lieberson Boston, Massachusetts $1.9B AUM 27.82% 1-Year Est. Return
AP
Atwood & Palmer Kansas City, Missouri $1.87B AUM 24.22% 1-Year Est. Return
COPPSERS
Commonwealth of Pennsylvania Public School Employees Retirement System Harrisburg, Pennsylvania $20.6B AUM 37.37% 1-Year Est. Return

Nautilus Advisors's VRTX Position: Q2 2026 in Review

Nautilus Advisors held its Vertex Pharmaceuticals (VRTX) position steady in Q2 2026 at 777 shares worth $377K. The position accounts for 0.22% of the portfolio, ranked #117.

Nautilus Advisors first reported a position in VRTX in Q1 2025 and has held it in 6 quarters since. 296 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

  • Nautilus Advisors held 777 shares of Vertex Pharmaceuticals worth $377K as of Q2 2026.
  • Nautilus Advisors left its Vertex Pharmaceuticals share count unchanged in Q2 2026.
  • Vertex Pharmaceuticals made up 0.22% of Nautilus Advisors's portfolio in Q2 2026, its #117 holding.
  • Nautilus Advisors first reported a position in Vertex Pharmaceuticals in Q1 2025 and has held it in 6 quarters since.
  • 296 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Nautilus Advisors's 13F filing for Q2 2026, filed 14 Jul 2026.